Anagenex

We are a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets. Machine learning has struggled in early stage drug discovery efforts because most of these efforts do not have enough data for the models to parse. Our technology solves the data problem with massively parallel biochemistry in the form of DNA Encoded Libraries (DELs), allowing us to analyze 100-1000x more compounds compared to traditional approaches. By feeding our algorithms with this data we can identify better compounds faster than competing solutions. We recently closed a substantial Series A, having assembled a highly interdisciplinary team of both bench and computational scientists and proven the technology by showing how our data and ML models improve on the state of the art by 3x-16x depending on the application. Come help us build the future of drug discovery!